Skip to content

A randomized, single-blind, controlled trial for robot-assisted cochlear implants for reducing basilar membrane damage

A randomized, single-blind, controlled trial for robot-assisted cochlear implants for reducing basilar membrane damage

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900026834
Enrollment
Unknown
Registered
2019-10-23
Start date
2019-11-01
Completion date
Unknown
Last updated
2019-10-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

sensory hearing loss

Interventions

robotic-assisted group:robotic-assisted electrode insertion
manual group:manual electrode insertion

Sponsors

Shanghai Ninth People's Hospital, School of Medicine, Shanghai Jiaotong University
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: 1. Postlingual deafness patients aged >=6 years, the deafness time is not more than 15 years; or the congenital pre-lingual deafness patients aged 1-6 years; the parental education level of the minors is junior college or above; 2. Suffering from bilateral severe to profound sensorineural hearing loss, hearing aids are ineffective or poorly effective; 3. CT/MRI did not see obvious abnormalities in the inner ear, suitable for unilateral cochlear implants; 4. ASA I to II; 5. No infection and good general condition, laboratory indicators are normal: (1) White blood cell count (4.0 ~ 10.0)x10^9/L; (2) percentage of neutrophils 50-70%; (3) Platelet count (100 ~ 300)x10^9/L; (4) Procalcitonin < 0.5ug/L; (5) The total bilirubin level is within the normal range (3.4 to 17.1 µmol/L); (6) Aspartate aminotransferase / alanine aminotransferase is within 2.5 times normal value (0 ~ 40U / L); (7) Serum creatinine is in the normal range (44-133umol/L).

Exclusion criteria

Exclusion criteria: 1. Previous systemic diseases (heart, nervous system, kidney, liver or coagulation system); 2. The patient currently uses other systemic diseases such as anticoagulant drugs, active or active infections; 3. Allergic to ceftriaxone; 4. Those who did not test according to the requirements of the programme; 5. Patients who refuse to participate for any reason; 6. The operation time of the electrode has been more than 2 hours before the electrode implantation; or other changes in the condition found in the surgery, such as the inability to implant the round window, the discovery of middle ear effusion and mucosal inflammation.

Design outcomes

Primary

MeasureTime frame
electrode position;

Countries

China

Contacts

Public ContactJia Huan

Department of Otolaryngology, Head & Neck Surgery, Shanghai Ninth People’s Hospital, affiliated to Shanghai Jiaotong University School of Medicine

huan_jia_orl@163.com+86 18019790827

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026